BC
DAWN

Bridgefront Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Bridgefront Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,345
Closed -$209K – 657
2025
Q1 		$209K Buy
26,345
+7,471
+40% +$80.5K 0.06% 505
2024
Q4 		$239K Buy
+18,874
New +$263K 0.08% 434

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's DAWN Position: Q2 2025 in Review

Bridgefront Capital sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 26,345 shares — an estimated $209K sold.

Bridgefront Capital first reported a position in DAWN in Q4 2024 and held it in 2 quarters. The position peaked at $239K in Q4 2024. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • Bridgefront Capital reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bridgefront Capital sold 26,345 Day One Biopharmaceuticals shares in Q2 2025, an estimated $209K.
  • Bridgefront Capital first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Bridgefront Capital's Day One Biopharmaceuticals position peaked at $239K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.